Learning from nemolizumab: A  promising therapy for prurigo nodularis

A recent phase 3 clinical trial (OLYMPIA 2) of nemolizumab, an anti –IL-31RA mAb for prurigo nodularis (PN), met the key primary end points of efficacy at week 16 and demonstrated benefit across all 5 secondary end points. Some of the more striking results were at the early time point of week 4, with significantly more patients reaching at least a 4-point reductio n in the Peak Pruritus Numerical Rating Scale itch score, almost complete itch relief (Peak Pruritus Numerical Rating Scale 
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research